Notice of Annual General Meeting of Shareholders

(Thomson Reuters ONE) -


The Board of Directors of Active Biotech AB (publ) has issued a notice to the
Annual General Meeting, which is to take place at 5 p.m. on Thursday, May
6, 2010, at the Company's premises at Scheelevägen 22 in Lund, Sweden.

Please see the attached notification, which is being published within short
inSvenska Dagbladet and Post- och Inrikes Tidningar.


Lund, April 6, 2010

ACTIVE BIOTECH AB (PUBL)

THE BOARD OF DIRECTORS



About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with R&D
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phases
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, and ANYARA
for use in cancer targeted therapy, primarily renal cancer. Further key projects
in clinical development comprise the three orally administered compounds TASQ
for prostate cancer, 57-57 for SLE and RhuDexTM for RA.


Active Biotech AB
P.O. Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication on April 6, 2010, at 8:30 a.m.



[HUG#1400601]





Active Biotech AB Notice of Annual General Meeting of Shareholders: http://hugin.info/1002/R/1400601/355855.pdf

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 06.04.2010 - 08:31 Uhr
Sprache: Deutsch
News-ID 18579
Anzahl Zeichen: 0

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 256 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Notice of Annual General Meeting of Shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech